- AbCellera, the stock, has had a woeful two plus years as a public company; however, AbCellera the business is performing brilliantly.
- The company recently announced an internally developed T-Cell engager program that it is looking to partner, likely at attractive terms for AbCellera, giving the company another avenue to monetization.
- The stock seems to be forming a bottom in the $8 range, potentially offering new investors an attractive long-term entry point.
For further details see:
AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment